CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology

CREATE Medicines, Inc., a clinical-stage biotechnology company specializing in in vivo immune programming, has successfully closed a $122 million Series B funding round. The financing was co-led by prominent investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with additional participation from Alexandria Venture Investments. This funding, announced on May 14, 2026, is earmarked to advance CREATE's clinical pipeline targeting autoimmune diseases and oncology.

The Series B funding will primarily support the development of CREATE's lead program, CRT-402, a next-generation CD19 targeted in vivo CAR-T therapy. This innovative therapy has shown promise in preclinical studies, demonstrating deep and durable B cell depletion in non-human primates, which could facilitate immune reset through the flexibility of repeat dosing. In addition to CRT-402, CREATE is also advancing a dual CAR CD19 x BCMA directed therapy aimed at addressing refractory autoimmune conditions, as well as therapies targeting high unmet needs in oncology, including the MT-303 program for frontline hepatocellular carcinoma.

CREATE Medicines has established a significant clinical footprint, having dosed over 50 patients across its in vivo CAR clinical programs, marking one of the largest clinical datasets in the field. The company's proprietary mRNA-LNP platform allows for the direct engineering of immune cells within the body, which is designed to expedite the transition from concept to clinical application. This iterative approach not only enhances the development of therapies but also informs subsequent clinical studies, reinforcing CREATE's position in the competitive biotechnology landscape.

The appointment of Ron Philip as Executive Chairman, alongside the addition of Brian Cuneo and Tom Thomas, PhD, to the Board of Directors, reflects the confidence investors have in CREATE's strategic direction and clinical trajectory. The leadership changes are anticipated to further strengthen the company's governance as it navigates the complexities of clinical development and regulatory approval in the biotechnology sector.

The successful fundraising round underscores the growing interest and investment in biotechnology, particularly in innovative therapies that leverage advanced technologies such as in vivo immune programming. As CREATE Medicines progresses with its clinical pipeline, it stands to play a significant role in reshaping treatment paradigms for autoimmune diseases and oncology. The broader market outlook suggests that as companies like CREATE continue to demonstrate clinical efficacy and scalability, investor confidence in the biotechnology sector may further solidify, potentially leading to increased funding and innovation in this vital area of healthcare.